Increased dependence on glutamine metabolism through the upregulation of glutamine transporters ASCT2 and GLS was also observed in cisplatin-resistant ovarian cancer cells, which were more sensitive to glutamine deprivation by GLS knockdown as compared to their cisplatin-sensitive counterparts [114,115]. This evidence concerns the gene GLS and ovarian cancer.